The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
Huang, X., El-Sayed, I. H., Qian, W., & El-Sayed, M. A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057254a · Cited by 5,436
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
Fluorination in Medicinal Chemistry: Methods, Strategies, and Recent Developments
Kirk, K. L. (2008) · Organic Process Research & Development · doi:10.1021/op700134j · Cited by 1,151
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
The pharmacology and clinical uses of tamoxifen
Furr, B. J. A., & Jordan, V. C. (1984) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(84)90043-3 · Cited by 864
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Integration of the extranuclear and nuclear actions of estrogen
Levin, E. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0390 · Cited by 708
Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
Lücking, U. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302209 · Cited by 672
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Affective disorders in five United States communities
Weissman, M. M., Leaf, P. J., Tischler, G. L., Blazer, D. G., Karno, M., Bruce, M. L., & Florio, L. P. (1988) · Psychological Medicine · doi:10.1017/s0033291700001975 · Cited by 628
Metabolism of Fluorine-Containing Drugs
Park, B. K., Kitteringham, N. R., & O'Neill, P. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.443 · Cited by 610
Gold Nanorods Mediate Tumor Cell Death by Compromising Membrane Integrity
Tong, L., Zhao, Y., Huff, T. B., Hansen, M. N., Wei, A., & Cheng, J. ‐. (2007) · Advanced Materials · doi:10.1002/adma.200701974 · Cited by 594
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Hyperthermic Effects of Gold Nanorods on Tumor Cells
Huff, T. B., Tong, L., Zhao, Y., Hansen, M. N., Cheng, J.-X., & Wei, A. (2007) · Nanomedicine · doi:10.2217/17435889.2.1.125 · Cited by 566
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Huss, J. M., Kopp, R. P., & Kelly, D. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206324200 · Cited by 479
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Top, S., Vessières, A., Leclercq, G., Quivy, J. I., Tang, J., Vaissermann, J., Huché, M., & Jaouen, G. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200305024 · Cited by 454
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
To ERR in the estrogen pathway
Giguére, V. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00592-1 · Cited by 401
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
Mechanisms of tamoxifen-induced apoptosis
Mandlekar, S., & Kong, A.-N. T. (2001) · Apoptosis · doi:10.1023/a:1012437607881 · Cited by 394
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Jordan, V. C. (1976) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(76)90030-x · Cited by 371
Kamei, Y., Ohizumi, H., Fujitani, Y., Nemoto, T., Tanaka, T., Takahashi, N., Kawada, T., Miyoshi, M., Ezaki, O., & Kakizuka, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135217100 · Cited by 357
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
Jordan, V. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706399 · Cited by 292
Dixit, V., Van den Bossche, J., Sherman, D. M., Thompson, D. H., & Andres, R. P. (2006) · Bioconjugate Chemistry · doi:10.1021/bc050335b · Cited by 282
McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., & Stewart, H. J. (1995) · BMJ · doi:10.1136/bmj.311.7011.977 · Cited by 276
Katzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., & Mangel, W. F. (1984) · PubMed · Cited by 276
Dreaden, E. C., Mwakwari, S. C., Sodji, Q. H., Oyelere, A. K., & El-Sayed, M. A. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9002212 · Cited by 268
4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ
Coward, P., Lee, D., Hull, M. V., & Lehmann, J. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151244398 · Cited by 265
Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand
Horard, B., & Vanacker, J. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310349 · Cited by 249
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Wu, X., Hawse, J. R., Subramaniam, M., Goetz, M. P., Ingle, J. N., & Spelsberg, T. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3933 · Cited by 225
Jordan, V. C., & Allen (née Naylor), K. E. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90156-5 · Cited by 214
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.43 · Cited by 213
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
Zarate, C. A., Singh, J. B., Carlson, P. J., Quiroz, J., Jolkovsky, L., Luckenbaugh, D. A., & Manji, H. K. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00530.x · Cited by 208
Signaling: cellular insights into the pathophysiology of bipolar disorder
Manji, H. K., & Lenox, R. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00929-x · Cited by 207
Anticancer and Immunosuppressive Properties of Bacterial Prodiginines
Williamson, N. R., Fineran, P. C., Gristwood, T., Chawrai, S. R., Leeper, F. J., & Salmond, G. P. (2007) · Future Microbiology · doi:10.2217/17460913.2.6.605 · Cited by 202
Tamoxifen: Catalyst for the change to targeted therapy
Jordan, V. C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.002 · Cited by 199
Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer
Turken, S., Siris, E., Seldin, D., Flaster, E., Hyman, G., & Lindsay, R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1086 · Cited by 194
Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors
Katori, M., & Majima, M. (2000) · Inflammation Research · doi:10.1007/s000110050605 · Cited by 193
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor
Jordan, V. C., & Koerner, S. (1975) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(75)90119-x · Cited by 186
Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse
Schmitt, K. C., & Reith, M. E. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05148.x · Cited by 180
JORDAN, V (2007) · Steroids · doi:10.1016/j.steroids.2007.07.009 · Cited by 177
Nabholtz, J. M., Bonneterre, J., Buzdar, A., Robertson, J. F. R., & Thürlimann, B. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00326-5 · Cited by 176
Selective estrogen receptor modulation: a personal perspective.
Jordan, V. C. (2001) · PubMed · Cited by 174
Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Peng, J., Sengupta, S., & Jordan, V. C. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788451833 · Cited by 171
Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder
Einat, H., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.004 · Cited by 166
Haynes, B. P., Dowsett, M., Miller, W. R., Dixon, J. M., & Bhatnagar, A. S. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00384-4 · Cited by 165
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer
Jordan, V. C. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-14-0092 · Cited by 165
Protein kinase C inhibits amyloid β‐peptide neurotoxicity by acting on members of the Wnt pathway
Garrido, J. L., Godoy, J., Alvarez, A., Bronfman, M., & Inestrosa, N. C. (2002) · The FASEB Journal · doi:10.1096/fj.02-0327fje · Cited by 163
Howell, S. J., Johnston, S. R. D., & Howell, A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2003.08.002 · Cited by 159
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
Park, W., & Jordan, V. C. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02282-7 · Cited by 158
Zhang, D., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124669 · Cited by 151
Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., & McDonnell, D. P. (2001) · PubMed · Cited by 150
Antiestrogens – Tamoxifen, SERMs and Beyond
Dhingra, K. (1999) · Investigational New Drugs · doi:10.1023/a:1006348907994 · Cited by 148
Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver
Larosche, I., Lettéron, P., Fromenty, B., Vadrot, N., Abbey‐Toby, A., Feldmann, G., Pessayre, D., & Mansouri, A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114546 · Cited by 148
A Series of Unconjugated Ferrocenyl Phenols: Prospects as Anticancer Agents
Hillard, E. A., Vessières, A., Bideau, F. L., Plażuk, D., Spera, D., Huché, M., & Jaouen, G. (2006) · ChemMedChem · doi:10.1002/cmdc.200500035 · Cited by 138
Selective estrogen receptor modulators in clinical practice: a safety overview
Ellis, A., Hendrick, V. M., Williams, R., & Komm, B. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1014799 · Cited by 128
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Bijl, M. J., van Schaik, R. H. N., Lammers, L. A., Albert Hofman, D., Vulto, A. G., van Gelder, T., Stricker, B. H. C., & Visser, L. E. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0272-2 · Cited by 126
Ahmad, I., & Shagufta, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.010 · Cited by 125
Self-citationTamoxifen: Teaching an old drug new tricks?
Grainger, D. J., & Metcalfe, J. C. (1996) · Nature Medicine · doi:10.1038/nm0496-381 · Cited by 125
CYP2D6 polymorphisms and the impact on tamoxifen therapy
Beverage, J. N., Sissung, T. M., Sion, A. M., Danesi, R., & Figg, W. D. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20892 · Cited by 123
Substituted phenanthrenes with basic amino side chains: A new series of anti-breast cancer agents
Shagufta, S., Srivastava, A. K., Sharma, R., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.10.002 · Cited by 122
Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis
Steiner, A. Z., Terplan, M., & Paulson, R. J. (2005) · Human Reproduction · doi:10.1093/humrep/deh840 · Cited by 122
Wiseman, H., Quinn, P. J., & Halliwell, B. B. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80918-k · Cited by 120
Protein kinase C isoforms as therapeutic targets in nervous system disease states
Battaini, F. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0893 · Cited by 115
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Dolan, K., Montgomery, S., Buchheit, B., DiDone, L., Wellington, M., & Krysan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01564-08 · Cited by 112
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRγ
Chao, E. Y. H., Collins, J. L., Gaillard, S. L., Miller, A. B., Wang, L., Orband‐Miller, L. A., Nolte, R. T., McDonnell, D. P., Willson, T. M., & Zuercher, W. J. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.030 · Cited by 97
Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
de Médina, P., Favre, G., & Poirot, M. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043352696 · Cited by 93
Cyrus, K., Wehenkel, M., Choi, E., Lee, H., Swanson, H. I., & Kim, K. (2010) · ChemMedChem · doi:10.1002/cmdc.201000146 · Cited by 91
Ewer, M. S., & Glück, S. (2009) · Cancer · doi:10.1002/cncr.24219 · Cited by 91
Katzenellenbogen, B. S., Carlson, K. E., & Katzenellenbogen, B. S. (1985) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(85)90210-9 · Cited by 91
Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug
Lazzeroni, M., Serrano, D., Dunn, B. K., Heckman‐Stoddard, B. M., Lee, O., Khan, S. A., & DeCensi, A. (2012) · Breast Cancer Research · doi:10.1186/bcr3233 · Cited by 89
The effects of aromatase inhibitors on lipids and thrombosis
Bundred, N. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602692 · Cited by 86
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance
Dowsett, M., Nicholson, R. I., & Pietras, R. J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9037-3 · Cited by 81
Are estrogen-related drugs new alternatives for the management of osteoarthritis?
Xiao, Y., Tian, F., Dai, M., Wang, W., Shao, L., & Zhang, L. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1045-7 · Cited by 79
Wiseman, H., Paganga, G., Rice-Evans, C. A., & Halliwell, B. B. (1993) · Biochemical Journal · doi:10.1042/bj2920635 · Cited by 78
Gennari, L., Merlotti, D., & Nuti, R. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6083 · Cited by 75
Jordan, V. C. (1988) · Cancer Investigation · doi:10.3109/07357908809082124 · Cited by 75
Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
Dezentjé, V. O., Guchelaar, H., Nortier, J. W. R., van de Velde, C. J. �., & Gelderblom, H. A. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2006 · Cited by 75
Lu, W. J., Xu, C., Pei, Z., Mayhoub, A. S., Cushman, M., & Flockhart, D. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1699-4 · Cited by 74
Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol
Baral, E., Nagy, E., & Berczi, I. (1995) · Cancer · doi:10.1002/1097-0142(19950115)75:2<591::aid-cncr2820750224>3.0.co;2-u · Cited by 71
Steffan, R. J., Matelan, E. M., Ashwell, M. A., Moore, W., Solvibile, W. R., Trybulski, E. J., Chadwick, C. C., Chippari, S. M., Kenney, T. F., Eckert, A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049194+ · Cited by 70
Degradation of target protein in living cells by small-molecule proteolysis inducer
Zhang, D., Baek, S.-H., Ho, A., & Kim, K. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.11.042 · Cited by 69
Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Pandey, R., Chander, R., & Sainis, K. B. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787582192 · Cited by 69
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
Kogan, N. M., Schlesinger, M., Priel, E., Rabinowitz, R., Berenshtein, E., Chevion, M., & Mechoulam, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0039 · Cited by 68
Watashi, K., Inoue, D., Hijikata, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704418200 · Cited by 67
Δαλέτος, Γ., de Voogd, N. J., Müller, W. E. G., Wray, V., Lin, W., Feger, D., Kubbutat, M. H. G., Aly, A. H., & Proksch, P. (2014) · Journal of Natural Products · doi:10.1021/np400633m · Cited by 64
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis
Ishikawa, T., Nakagawa, H., Hagiya, Y., Nonoguchi, N., Miyatake, S., & Kuroiwa, T. (2010) · Advances in Pharmacological Sciences · doi:10.1155/2010/587306 · Cited by 59
Baumann, C. K., & Castiglione‐Gertsch, M. (2007) · Drugs · doi:10.2165/00003495-200767160-00004 · Cited by 58
Campbell, C. H., Bulayeva, N. N., Brown, D. B., Gametchu, B., & Watson, C. S. (2002) · The FASEB Journal · doi:10.1096/fj.02-0182com · Cited by 52
Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder
Ali, S. M., Ahmad, A., Shahabuddin, S., Ahmad, M. U., Sheikh, S., & Ahmad, I. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.02.024 · Cited by 51
Self-citationde Oliveira, A. C., Hillard, E. A., Pigeon, P., Rocha, D. D., Rodrigues, F. A. R., Montenegro, R. C., Costa-Lotufo, L. V., Goulart, M. O. F., & Jaouen, G. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.043 · Cited by 49
Meegan, M. J., Hughes, R. B., Lloyd, D. G., Williams, D. C., & Zisterer, D. M. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001119l · Cited by 49
Synthesis and growth inhibition activity of fluorinated derivatives of tamoxifen
Malo‐Forest, B., Landelle, G., Roy, J., Lacroix, J., Gaudreault, R. C., & Paquin, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.057 · Cited by 46
Khan, S. Z., Longland, C. L., & Michelangeli, F. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00505-0 · Cited by 46
Lv, W., Liu, J., Skaar, T. C., Flockhart, D. A., & Cushman, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501218e · Cited by 46
Siles, R., Ackley, J. F., Hadimani, M. B., Hall, J. J., Mugabe, B. E., Guddneppanavar, R., Monk, K. A., Chapuis, J., Pettit, G. R., Chaplin, D. J., et al. (2008) · Journal of Natural Products · doi:10.1021/np070377j · Cited by 45
Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer
Arsenyan, P., Paegle, E., Домрачева, И., Gulbe, A., Kanepe, I., & Shestakova, I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.088 · Cited by 43
Chemoprevention for High-Risk Women: Tamoxifen and Beyond
Fabian, C. J., & Kimler, B. F. (2001) · The Breast Journal · doi:10.1046/j.1524-4741.2001.21570.x · Cited by 42
Recent Advances in Understanding the Molecular Mechanisms of Tamoxifen Action
Friedman, Z. Y. (1998) · Cancer Investigation · doi:10.3109/07357909809115779 · Cited by 41
Ansari, M. I., Hussain, M. K., Arun, A., Chakravarti, B., Konwar, R., & Hajela, K. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.035 · Cited by 40
Wiseman, H., Cannon, M., Arnstein, H. R. V., & Halliwell, B. B. (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(93)90021-r · Cited by 38
Thomas, T., Gallo, M. A., & Thomas, T. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332880 · Cited by 37
4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II
Christodoulou, M. S., Zarate, M., Ricci, F., Damia, G. L. M., Pieraccini, S., Dapiaggi, F., Sironi, M., Presti, L. L., García‐Argáez, A. N., Via, L. D., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.090 · Cited by 36
Rickert, E., Oriana, S., Hartman-Frey, C., Long, X., Webb, T. T., Nephew, K. P., & Weatherman, R. V. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900461h · Cited by 35
Structure–activity relationship study of diphenylamine-based estrogen receptor (ER) antagonists
Ohta, K., Chiba, Y., Kaise, A., & Endo, Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.022 · Cited by 35
Tamoxifen: the drug that came in from the cold
Hughes‐Davies, L., Caldas, C., & Wishart, G. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605231 · Cited by 34
Shoda, T., Kato, M., Harada, R., Fujisato, T., Okuhira, K., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.002 · Cited by 32
Nagahara, Y., Shiina, I., Nakata, K., Sasaki, A., Miyamoto, T., & Ikekita, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00709.x · Cited by 32
Schobert, R., Bernhardt, G., Biersack, B., Bollwein, S., Fallahi, M., Grotemeier, A., & Hammond, G. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200600173 · Cited by 32
Photodynamic cell‐kill analysis of breast tumor cells with a tamoxifen‐pyropheophorbide conjugate
Fernández‐Gacio, A., Fernandez‐Marcos, C., Swamy, N., Dunn, D., & Ray, R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20932 · Cited by 31
Optimising endocrine approaches for the chemoprevention of breast cancer
Jordan, V. C. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.012 · Cited by 30
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
Shoda, T., Okuhira, K., Kato, M., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.078 · Cited by 30
Lv, W., Liu, J., Skaar, T. C., O’Neill, E., Yu, G., Flockhart, D. A., & Cushman, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01677 · Cited by 30
Locating the binding sites of antitumor drug tamoxifen and its metabolites with DNA
Bourassa, P., Thomas, T., & Tajmir‐Riahi, H. A. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.02.028 · Cited by 28
Synthesis and biological evaluation of novel tamoxifen analogues
Christodoulou, M. S., Fokialakis, N., Passarella, D., García‐Argáez, A. N., Gia, O. M., Pongratz, I., Via, L. D., & Haroutounian, S. A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.012 · Cited by 28
Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism
Ahmed, N. S., Elghazawy, N. H., ElHady, A. K., Engel, M., Hartmann, R. W., & Abadi, A. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.026 · Cited by 28
Andersson, A., Bernardi, A. I., Stubelius, A., Nurkkala, M., Ohlsson, C., Carlsten, H., & Islander, U. (2015) · Rheumatology · doi:10.1093/rheumatology/kev355 · Cited by 28
Shiina, I., Sano, Y., Nakata, K., Kikuchi, T., Sasaki, A., Ikekita, M., Nagahara, Y., Hasome, Y., Yamori, T., & Yamazaki, K. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.11.005 · Cited by 27
Nilsson, U. W., Jönsson, J., & Dabrosin, C. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.015 · Cited by 26
SULFONES: AN IMPORTANT CLASS OF ORGANIC COMPOUNDS WITH DIVERSE BIOLOGICAL ACTIVITIES
Ahmad, I., & Shagufta, S. (2015) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 26
Self-citationPAMAM dendrimers in drug delivery: loading efficacy and polymer morphology
Chanphai, P., Bekale, L. A., Sanyakamdhorn, S., Agudelo, D., Bérubé, G., Thomas, T., & Tajmir‐Riahi, H. A. (2017) · Canadian Journal of Chemistry · doi:10.1139/cjc-2017-0115 · Cited by 25
A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor
Hasegawa, M., Yasuda, Y., Tanaka, M., Nakata, K., Umeda, E., Wang, Y., Watanabe, C., Uetake, S., Kunoh, T., Shionyu, M., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.009 · Cited by 22
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?
Mikelman, S. R., Mardirossian, N., & Gnegy, M. E. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.08.004 · Cited by 22
Kaur, G., Mahajan, M. P., Pandey, M. K., Singh, P., Ramisetti, S. R., & Sharma, A. K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.008 · Cited by 21
Archana, S., Geesala, R., Rao, N. B., Satpati, S., Puroshottam, G., Panasa, A., Dixit, A., Das, A., & Srivastava, A. K. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.077 · Cited by 20
Pharmacologic treatment of male breast cancer
Hayes, T. G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903200634 · Cited by 20
Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity
Schneider, M. R., Hartmann, R. W., Sinowatz, F., & Amselgruber, W. M. (1986) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00395920 · Cited by 19
Hawco, C., Marchal, E., Uddin, M. I., Baker, A. E. G., Corkery, D., Dellaire, G., & Thompson, A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.07.042 · Cited by 19
High Affinity Fluorescent Ligands for the Estrogen Receptor
Abendroth, F., Solleder, M., Mangoldt, D., Welker, P., Licha, K., Weber, M., & Seitz, O. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201403489 · Cited by 18
N-Alkoxypyrazoles as biomimetics for the alkoxyphenyl group in tamoxifen
Wenckens, M., Jakobsen, P., Vedsø, P., Huusfeldt, P. O., Gissel, B., Barfoed, M., Brockdorff, B. L., Lykkesfeldt, A. E., & Begtrup, M. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00566-7 · Cited by 18
Auger, S., Mérand, Y., Pelletier, J. D., Poirier, D., & Labrie, F. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00014-q · Cited by 16
A new selective fluorescent probe based on tamoxifen
Ho, L. A., Thomas, E., McLaughlin, R. A., Flematti, G. R., & Fuller, R. O. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.028 · Cited by 16
Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues
Abdellatif, K. R. A., Belal, A., & Omar, H. A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.056 · Cited by 16
Yu, B., Qin, Z., Wijewickrama, G. T., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800435m · Cited by 14
Carpenter, C., Sorenson, R. J., Jin, Y., Kłossowski, S., Cierpicki, T., Gnegy, M. E., & Showalter, H. D. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.002 · Cited by 14
Effects of tamoxifen on ischemia-induced angiogenesis in the mouse lung
Wagner, E. M., Gallagher, S. J., Reddy, S. P., & Mitzner, W. (2003) · Angiogenesis · doi:10.1023/a:1025822127847 · Cited by 9
Meegan, M. J., Barrett, I., Zimmermann, J., et al. (2007) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360701503232 · Cited by 9
Tajmir Riahi, H. A. (2016) · Journal of Nanomedicine Research · doi:10.15406/jnmr.2016.04.00080 · Cited by 9
Cited by
Cancer associated-fibroblast-derived exosomes in cancer progression
Li, C., Teixeira, A. F., Zhu, H.-J., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 336
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39
Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells
Zhao, W., Ma, J., Zhang, Q., Zhang, H., Ma, W., Li, S., piao, Y., Zhao, S., Dai, S., & Tang, D. (2024) · Cell Biology International · doi:10.1002/cbin.12123 · Cited by 17
“by ~40% (Azuma et al., 2021; Haque et al., 2016; Legha, 1988; Osborne, 1998; Shagufta & Ahmad, 2018; Yang et al., 2013).”
SYNTHESIS OF TAMOXIFEN DERIVATIVES AND THEIR BIOLOGICAL ACTIVITIES
Tandon, N., Tandon, N., & Tandon, R. (2020) · PLANT ARCHIVES · doi:10.51470/plantarchives.2021.v21.s1.376
Metadata
- Authors
- Shagufta, & Ahmad, I.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 143
- Pages
- 515-531
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2770369177
- Cited by
- 263
- References
- 157
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.